In preclinical research, several HSP90 inhibitors have demonstrated effectiveness against myeloma, and at least three of these drugs have proceeded to Phase I/II clinical trials for the treatment of relapsed/refractory myeloma (Cavenagh et al., 2017). Here, HSP90AA1 is linked to plasma cell myeloma.